EFFECT OF FINERENONE IN DIABETIC NEPHROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY IN BANGLADESH

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/06404009192f0b14ff6d621b2a5aa207.pdf

Abstract Title *

EFFECT OF FINERENONE IN DIABETIC NEPHROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY IN BANGLADESH

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Harun ur Rashid rashid@bol-online.com Kidney Fondation Nephrology Dhaka Bangladesh *

Co-author 2

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Diabetic Nephropathy (DN) is a major global health concern with increasing prevalence, especially in low- and middle-income countries like Bangladesh. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown reno- and cardioprotective potential in large international trials, but local data in Bangladeshi populations remain scarce.

Methods

This prospective observational study included 90 DN patients, divided into a treatment group receiving Finerenone 10 mg daily (n=30) and a control group on standard therapy (n=60). Renal (creatinine, eGFR, urea, ), electrolyte and urinary findings were assessed and compared between groups at baseline, 3 months, and 6 months. Repeated Measures ANOVA and Generalized Estimating Equations (GEE) were applied for analysis.

Results

Finerenone showed no significant impact on renal function compared with controls. In treatment group, serum creatinine rose slightly over time, while eGFR and urea remained stable. Electrolyte analysis revealed a transient increase in serum potassium at the 3rd month (p=0.008), which normalized by 6 months. Urinary albumin remained unchanged

Conclusion

Finerenone was generally safe and well-tolerated in CKD patients over six months, with stable renal function and manageable electrolyte variations.

Kewords